{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T08:09:32Z","timestamp":1792656572121,"version":"4.5.0"},"reference-count":17,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2013,8,9]],"date-time":"2013-08-09T00:00:00Z","timestamp":1376006400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/2.0"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["BMC Endocr Disord"],"published-print":{"date-parts":[[2013,12]]},"DOI":"10.1186\/1472-6823-13-29","type":"journal-article","created":{"date-parts":[[2013,8,9]],"date-time":"2013-08-09T12:14:02Z","timestamp":1376050442000},"source":"Crossref","is-referenced-by-count":7,"title":["Development of skin hypopigmentation in a patient with metastatic papillary carcinoma thyroid treated with Sorafenib"],"prefix":"10.1186","volume":"13","author":[{"given":"Syed Zubair","family":"Hussain","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ali","family":"Asghar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mubasher","family":"Ikram","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Najmul","family":"Islam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2013,8,9]]},"reference":[{"issue":"1","key":"182_CR1","doi-asserted-by":"publisher","first-page":"43","DOI":"10.3322\/canjclin.57.1.43","volume":"57","author":"A Jemal","year":"2007","unstructured":"Jemal A, Siegel R, Ward E, Murray T, Xu J, Thun MJ: Cancer statistics, 2007. CA Cancer J Clin. 2007, 57 (1): 43-66. 10.3322\/canjclin.57.1.43.","journal-title":"CA Cancer J Clin"},{"key":"182_CR2","volume-title":"Cancer facts and figures 2010","author":"American cancer society","year":"2010","unstructured":"American cancer society: Cancer facts and figures 2010. 2010, Atlanta: American cancer society"},{"issue":"6","key":"182_CR3","doi-asserted-by":"publisher","first-page":"692","DOI":"10.1016\/S0002-9610(96)00310-8","volume":"172","author":"AR Shaha","year":"1996","unstructured":"Shaha AR, Shah JP, Loree TR: Patterns of nodal and distant metastasis based on histologic varieties in differentiated carcinoma of the thyroid. Am J Surg. 1996, 172 (6): 692-694. 10.1016\/S0002-9610(96)00310-8.","journal-title":"Am J Surg"},{"issue":"3","key":"182_CR4","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1210\/jcem-67-3-501","volume":"67","author":"JJ Ruegemer","year":"1988","unstructured":"Ruegemer JJ, Hay ID, Bergstralh EJ, Ryan JJ, Offord KP, Gorman CA: Distant metastases in differentiated thyroid carcinoma: a multivariate analysis of prognostic variables. J Clin Endocrinol Metab. 1988, 67 (3): 501-508. 10.1210\/jcem-67-3-501.","journal-title":"J Clin Endocrinol Metab"},{"issue":"2","key":"182_CR5","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1016\/S1072-7515(03)00332-6","volume":"197","author":"M Shoup","year":"2003","unstructured":"Shoup M, Stojadinovic A, Nissan A, Ghossein RA, Freedman S, Brennan MF, Shah JP, Shaha AR: Prognostic indicators of outcomes in patients with distant metastases from differentiated thyroid carcinoma. J Am Coll Surg. 2003, 197 (2): 191-197. 10.1016\/S1072-7515(03)00332-6.","journal-title":"J Am Coll Surg"},{"issue":"Suppl 2","key":"182_CR6","doi-asserted-by":"publisher","first-page":"S37","DOI":"10.1038\/modpathol.2008.10","volume":"21","author":"YE Nikiforov","year":"2008","unstructured":"Nikiforov YE: Thyroid carcinoma: molecular pathways and therapeutic targets. Mod Pathol. 2008, 21 (Suppl 2): S37-S43.","journal-title":"Mod Pathol"},{"issue":"4","key":"182_CR7","doi-asserted-by":"publisher","first-page":"1737","DOI":"10.1210\/jcem.87.4.8388","volume":"87","author":"RM Tuttle","year":"2002","unstructured":"Tuttle RM, Fleisher M, Francis GL, Robbins RJ: Serum vascular endothelial growth factor levels are elevated in metastatic differentiated thyroid cancer but not increased by short-term TSH stimulation. J Clin Endocrinol Metab. 2002, 87 (4): 1737-1742. 10.1210\/jc.87.4.1737.","journal-title":"J Clin Endocrinol Metab"},{"issue":"2","key":"182_CR8","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1016\/j.jaad.2008.06.034","volume":"60","author":"C Robert","year":"2009","unstructured":"Robert C, Mateus C, Spatz A, Wechsler J, Escudier B: Dermatologic symptoms associated with the multikinase inhibitor sorafenib. J Am Acad Dermatol. 2009, 60 (2): 299-305. 10.1016\/j.jaad.2008.06.034.","journal-title":"J Am Acad Dermatol"},{"issue":"26","key":"182_CR9","doi-asserted-by":"publisher","first-page":"4293","DOI":"10.1200\/JCO.2005.01.3441","volume":"24","author":"GK Abou-Alfa","year":"2006","unstructured":"Abou-Alfa GK, Schwartz L, Ricci S, Amadori D, Santoro A, Figer A, De Greve J, Douillard JY, Lathia C, Schwartz B: Phase II study of sorafenib in patients with advanced hepatocellular carcinoma. J Clin Oncol. 2006, 24 (26): 4293-4300. 10.1200\/JCO.2005.01.3441.","journal-title":"J Clin Oncol"},{"issue":"2","key":"182_CR10","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1056\/NEJMoa060655","volume":"356","author":"B Escudier","year":"2007","unstructured":"Escudier B, Eisen T, Stadler WM, Szczylik C, Oudard S, Siebels M, Negrier S, Chevreau C, Solska E, Desai AA: Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med. 2007, 356 (2): 125-134. 10.1056\/NEJMoa060655.","journal-title":"N Engl J Med"},{"issue":"5","key":"182_CR11","doi-asserted-by":"publisher","first-page":"643","DOI":"10.1530\/EJE-12-0405","volume":"167","author":"TC Schneider","year":"2012","unstructured":"Schneider TC, Abdulrahman RM, Corssmit EP, Morreau H, Smit JW, Kapiteijn E: Long-term analysis of the efficacy and tolerability of sorafenib in advanced radio-iodine refractory differentiated thyroid carcinoma: final results of a phase II trial. Eur J Endocrinol. 2012, 167 (5): 643-650. 10.1530\/EJE-12-0405.","journal-title":"Eur J Endocrinol"},{"issue":"29","key":"182_CR12","doi-asserted-by":"publisher","first-page":"4714","DOI":"10.1200\/JCO.2008.16.3279","volume":"26","author":"V Gupta-Abramson","year":"2008","unstructured":"Gupta-Abramson V, Troxel AB, Nellore A, Puttaswamy K, Redlinger M, Ransone K, Mandel SJ, Flaherty KT, Loevner LA, O\u2019Dwyer PJ: Phase II trial of sorafenib in advanced thyroid cancer. J Clin Oncol. 2008, 26 (29): 4714-4719. 10.1200\/JCO.2008.16.3279.","journal-title":"J Clin Oncol"},{"issue":"10","key":"182_CR13","doi-asserted-by":"publisher","first-page":"1675","DOI":"10.1200\/JCO.2008.18.2717","volume":"27","author":"RT Kloos","year":"2009","unstructured":"Kloos RT, Ringel MD, Knopp MV, Hall NC, King M, Stevens R, Liang J, Wakely PE, Vasko VV, Saji M: Phase II trial of sorafenib in metastatic thyroid cancer. J Clin Oncol. 2009, 27 (10): 1675-1684. 10.1200\/JCO.2008.18.2717.","journal-title":"J Clin Oncol"},{"key":"182_CR14","volume-title":"ASCO","author":"MS Brose","year":"2013","unstructured":"Brose MS: \u2018Sorafenib in locally advanced or metastatic patients with radioactive iodine-refractory differentiated thyroid cancer: the phase III DECISION trial\u2019. ASCO. 2013, Abstract 4 MedPage Today, June 04, 2013."},{"issue":"7","key":"182_CR15","doi-asserted-by":"publisher","first-page":"886","DOI":"10.1001\/archderm.144.7.886","volume":"144","author":"J Autier","year":"2008","unstructured":"Autier J, Escudier B, Wechsler J, Spatz A, Robert C: Prospective study of the cutaneous adverse effects of sorafenib, a novel multikinase inhibitor. Arch Dermatol. 2008, 144 (7): 886-892. 10.1001\/archderm.144.7.886.","journal-title":"Arch Dermatol"},{"issue":"5","key":"182_CR16","doi-asserted-by":"publisher","first-page":"1045","DOI":"10.1111\/j.1365-2133.2009.09290.x","volume":"161","author":"WJ Lee","year":"2009","unstructured":"Lee WJ, Lee JL, Chang SE, Lee MW, Kang YK, Choi JH, Moon KC, Koh JK: Cutaneous adverse effects in patients treated with the multitargeted kinase inhibitors sorafenib and sunitinib. Br J Dermatol. 2009, 161 (5): 1045-1051. 10.1111\/j.1365-2133.2009.09290.x.","journal-title":"Br J Dermatol"},{"issue":"3","key":"182_CR17","doi-asserted-by":"publisher","first-page":"378","DOI":"10.1016\/j.critrevonc.2011.08.005","volume":"82","author":"S Bracarda","year":"2012","unstructured":"Bracarda S, Ruggeri EM, Monti M, Merlano M, D\u2019Angelo A, Ferrau F, Cortesi E, Santoro A: Early detection, prevention and management of cutaneous adverse events due to sorafenib: recommendations from the Sorafenib working group. Crit Rev Oncol Hematol. 2012, 82 (3): 378-386. 10.1016\/j.critrevonc.2011.08.005.","journal-title":"Crit Rev Oncol Hematol"}],"container-title":["BMC Endocrine Disorders"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1186\/1472-6823-13-29\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/1472-6823-13-29.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/1472-6823-13-29","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/1472-6823-13-29.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,1,22]],"date-time":"2019-01-22T11:49:52Z","timestamp":1548157792000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcendocrdisord.biomedcentral.com\/articles\/10.1186\/1472-6823-13-29"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,8,9]]},"references-count":17,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2013,12]]}},"alternative-id":["182"],"URL":"https:\/\/doi.org\/10.1186\/1472-6823-13-29","relation":{},"ISSN":["1472-6823"],"issn-type":[{"value":"1472-6823","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,8,9]]},"article-number":"29"}}